Bone Biologics Corporation (BBLG)
USD 1.03
(-1.9%)
USD 1.03
(-1.9%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.55 Million | -3.56 Million | -1.22 Million | -426.93 Thousand | -3.25 Million | -4.1 Million |
| Net Income | -8.94 Million | -1.48 Million | -1.61 Million | -1.82 Million | -3.42 Million | -4.43 Million |
| Depreciation & Amortization | - | - | - | - | 50.00 | 96.00 |
| Deferred income taxes | - | - | - | - | -277.74 Thousand | -716.78 Thousand |
| Stock-based compensation | 152.59 Thousand | 266.63 Thousand | 207.03 Thousand | 60 Thousand | 49.69 Thousand | 516.63 Thousand |
| Change in working capital | 132.92 Thousand | -168.37 Thousand | -320.48 Thousand | 399.68 Thousand | 143.78 Thousand | 145.53 Thousand |
| Other non-cash items | -892.69 Thousand | -2.18 Million | 495.55 Thousand | 938.07 Thousand | 257.8 Thousand | 380.02 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 5.04 Million | 4.42 Million | 7.9 Million | 402.78 Thousand | 2.32 Million | 4.36 Million |
| Debt repayment | - | - | -10.6 Thousand | -402.78 Thousand | -2.32 Million | -600 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 5.04 Million | 4.42 Million | 6.85 Million | - | - | 4.36 Million |
| Other Financing Activities | 5044.16 | 4429.86 | 1.05 Million | 805.57 Thousand | 4.64 Million | 4.36 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 255.87 Thousand | 788.55 Thousand | -365.48 Thousand | 333 Thousand | -64.82 Thousand | -66.9 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -122.95 Thousand | -956.92 Thousand | 45 Thousand | 66.68 Thousand | 208.6 Thousand | 212.44 Thousand |
| Cash at beginning of period | 7.53 Million | 6.67 Million | - | 24.14 Thousand | 955.37 Thousand | 690.27 Thousand |
| Cash at end of period | 3.02 Million | 7.53 Million | 6.67 Million | - | 24.14 Thousand | 955.37 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -4.51 Million | 862.94 Thousand | 6.67 Million | -24.14 Thousand | -931.22 Thousand | 265.09 Thousand |
| Free Cash Flow | -9.55 Million | -3.56 Million | -1.22 Million | -426.93 Thousand | -3.25 Million | -4.1 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -783.73 Thousand | -865.97 Thousand | -1.54 Million | -8.94 Million | -1.91 Million | -1.76 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 17.44 Thousand | 52.68 Thousand | 71.13 Thousand | 152.59 Thousand | 20.02 Thousand | 16.67 Thousand |
| Change in working capital | -118.79 Thousand | -452.81 Thousand | -514.5 Thousand | 132.92 Thousand | -494.89 Thousand | -609.9 Thousand |
| Other non-cash items | -79.02 Thousand | 152.44 Thousand | -24.76 Thousand | -892.69 Thousand | -160.64 Thousand | -1.27 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 299.00 | 1.5 Million | 591.99 Thousand | 5.04 Million | - | 4.45 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 299.00 | 1.5 Million | 591.99 Thousand | 5.04 Million | - | 4.45 Million |
| Other Financing Activities | 299.00 | 1.5 Million | 592.00 | 5044.16 | - | 4452.16 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 85.68 Thousand | -137.07 Thousand | 41.61 Thousand | 255.87 Thousand | -586.37 Thousand | -590.09 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -204.47 Thousand | -315.73 Thousand | -556.12 Thousand | -122.95 Thousand | 91.48 Thousand | -19.8 Thousand |
| Cash at beginning of period | 3.22 Million | 3.02 Million | 4.45 Million | 7.53 Million | 7 Million | 6.18 Million |
| Cash at end of period | 2.33 Million | 3.22 Million | 3.02 Million | 3.02 Million | 4.45 Million | 7 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -895.56 Thousand | 201.06 Thousand | -1.42 Million | -4.51 Million | -2.55 Million | 819.49 Thousand |
| Free Cash Flow | -895.86 Thousand | -1.3 Million | -2.01 Million | -9.55 Million | -2.55 Million | -3.63 Million |
SYS1
GTBP
GOD
9761
4235
3494